CD274 and melanoma: In a recent study by Cappelletto et al., the authors evaluated a large collection of cytokines with biomarker potential which included FKN together with soluble PD-L1 in plasma and sera from melanoma and NSCLC patients treated with anti-PD-1 and anti-PD-L1 immunotherapies [125].